Investor Relations

IR Overview

FluoroPharma Medical, Inc. (OTCQB: FPMI)

FluoroPharma Medical, Inc. (FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.

Quick Links

  
Corporate Presentation SEC Filings

Recent News


Share Statistics

Outstanding: 22,440,894
(as of May 14, 2012)

Company Information

FluoroPharma Medical, Inc.
500 Boylston Street
Suite 1600
Boston, MA 02116

8 Hillside Ave
Suite 207
Montclair, NJ 07042

Management Team

David R. Elmaleh, PhD
Chairman, Director and Chief Scientific Advisor

Thijs Spoor
Director, CEO & President

Boyan Goumnerov, MD
COO & Vice President Clinical Trials

Investor Relations

Thijs Spoor
tspoor@fluoropharma.com

Transfer Agent

Holladay Stock Transfer
2939 N. 67th Place
Scottsdale, AZ 85251
480-481-3940

Auditors

MartinelliMick PLLC
Rock Pointe Tower
316 W Boone, Ste 777
Spokane, WA 99201
Tel: (509) 443-5749